Coralville, IA – According to filings with the U.S. Securities and Exchange Commission, Digital Diagnostics is raising $54,999,822.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Bertrand played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Digital Diagnostics
Digital Diagnostics is a pioneering AI diagnostics company on a mission to transform the quality, accessibility and affordability of healthcare. Founded and led by Dr. Michael Abramoff, an ophthalmologist, neuroscientist and computer engineer, Digital Diagnostics developed a patented biomarker-based approach to build autonomous algorithms that make clinical decisions without human intervention. Digital Diagnostics and its flagship product IDx-DR, an autonomous AI system FDA-authorized to diagnose diabetic retinopathy and diabetic macular edema, has proven that intelligent diagnostic platforms can be used safely, efficiently and equitably to improve patient outcomes. As it expands into other diagnostic capabilities, Digital Diagnostics has paved the way for automated diagnosis to become a new standard of care that will contribute significantly to democratizing healthcare.

To learn more about Digital Diagnostics, visit http://www.eyediagnosis.net/

Contact:
John Bertrand, Chief Executive Officer
319-248-5620
jbertrand@eyediagnosis.net
https://www.linkedin.com/in/john-bertrand-b193094/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved